Oxford Cannabinoid Technologies Holdings Plc
🇬🇧United Kingdom
Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: OCT461201 100 mgDrug: OCT461201 150 mgDrug: OCT461201 450 mgDrug: OCT461201 50 mgDrug: Placebo
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Oxford Cannabinoid Technologies Holdings PLC
- Target Recruit Count
- 32
- Registration Number
- NCT06398925
- Locations
- 🇬🇧
Simbec-Orion, Merthyr Tydfil, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath